One month after the first dose of E5, males show better results than females; as for the lifespan study, at 41 months of age, three treated rats are still alive.The first results of the new mixed-gender E5 study confirmed some observations from the previous studies. One confirmation is that males showed again a potent response to E5. The other confirmation is that females, while showing a considerable response, displayed a less potent response than males. The results, referring to the inflammatory cytokines IL-6 and TNF-alpha, were obtained one month after the first dose of E5. The graphs below show the results of the two cytokines on days 0, 15 and 30. According to Akshay Sanghavi, Yuvan’s CEO, "Harold had a very strong hunch that there is gender variance in E5 results from the preceding and still ongoing lifespan study, and the first-month results totally confirm Harold’s hypothesis", referring to Dr. Harold Katcher, CSO of Yuvan. In this study, 24 Sprague Dawley rats, between 18 and 20 months of age, were divided into two groups: 12 treated and 12 controls. In each group of 12 rats, there are six males and six females. The doses of E5 are applied every 45 days, half of the time interval used in the previous studies. As for the lifespan study, with only female rats that started the treatment older, at 24 months of age, three E5-treated rats are still alive at 41 months of age, exceeding to a considerable extent the average longevity of the study control rats and the average longevity of the species. According to Sanghavi, "every day they live is adding to the result, especially since the female rats showed a lower response to E5 in some aspects". Initially, the study had 8 treated rats and 8 control rats, and none of the control rats are still alive.
|
